RxDoctor Payments Data

Jed Gorden, MD

Pulmonary Disease · Seattle, WANPI 1275630147

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 87.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $43,947 and has fallen 82.6% since, to $7,662 in 2025. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$235,788in general payments, 2019–2025

Across 246 payments — averaging $958.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$206K
  • Daiichi Sankyo Inc.$17K
  • Verathon Inc.$5K
  • Pinnacle Biologics, Inc$3K
  • Astrazeneca UK Limited$2K
  • Pfizer$1K
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$105,42645%
  • Speaking & faculty fees$100,34543%
  • Travel & lodging$24,10010%
  • Food & beverage$5,9003%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$235,788 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$116,418
Medicare patients
142
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →